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i. introduction
Health care is an industry unlike any other. It is 
comprised of both goods and services like many other 
commercial industries, including the agriculture, airline, 
and housing industries. It is a necessity for survival in 
terms of preventative medicine, pharmaceutical drugs, 
or life-saving procedures, and a luxury for those who 
can afford often-expensive cosmetic procedures or 
medical devices. Like any other commercial industry 
in our free market society, it requires regulation and 
licensing to protect people from counterfeits, poor 
quality, and deliberate contamination. Why are we as a 
society so unwilling to devote the necessary resources 
to devise and implement quality control measures in 
an industry like health care, where quality services 
and pharmaceuticals are the only means of survival for 
millions of Americans?
The complexity of importation and reimportation of 
prescription drugs cannot be understated, as it is both a 
national and international issue involving economics, 
public policy, private industry, intellectual property, 
and criminal law. This paper explores why our country 
has failed to devote the necessary resources to health 
care, and in particular prescription drug importation 
and reimportation, in an economic and legal context. 
It analyzes the unique market characteristics of 
the pharmaceutical industry, the framework of 
pharmaceutical drug regulation including prescription 
drug importation, and the regulatory structure of 
importation in general. Part II provides background on 
the health care industry and prescription drug markets 
in the U.S. and abroad. Part III examines legislative 
proposals for drug importation and reimportation 
and the controversial congressional reaction to 
rising prescription drug prices in the U.S. Part IV 
addresses counterarguments primarily put forth by 
pharmaceutical companies and the U.S. Food and 
Drug Administration (FDA), against drug importation 
and reimportation. Part V discusses a variety of laws 
and regulations pertaining to the cross border flow 
of goods, services, and people into the U.S. Part VI 
suggests methods of reform. Part VII concludes 
that, regardless of whether legalized importation is 
the answer, safety inadequacies in the regulation of 
imported drugs must be improved.
ii. health Care and Prescription drugs: 
rising Cost
A. The Current Landscape of Health Care Spending in 
the United States
According to a report published by economists and 
actuaries with the Office of the Actuary at the Centers 
for Medicare and Medicaid Services (CMS)1, in 2008, 
health care spending in the United States (U.S.) was 
16.6% of the Gross Domestic Product (GDP).2 This 
report projects that by 2018, health care spending will 
amount to 20.3% of GDP — or $4.4 trillion.3
We as a nation are approaching a crossroads. Growth 
in health care spending as a part of our national 
economy and increasing costs and lack of affordability 
are on a path towards each other at an alarming speed. 
Budget shortfalls and fiscal deficits are forcing states 
to redistribute funds to accommodate critical spending 
needs. Data suggest that the spike in personal health 
care spending is primarily attributable to rising 
medical care prices, along with the effects of the 2008-
2009 recession, an increase in Medicaid enrollment, 
increasing numbers of uninsured Americans, and the 
decrease in GDP experienced in 2009,4 as contributing 
factors.5 The U.S. spends more than any other 
developing country on health care, both in terms of per 
capita spending and percentage of GDP.6 To highlight 
American spending priorities, health care spending is 
4.3 times greater than the amount spent on national 
defense.7 While the recession has led to a deceleration 
in the growth of health care spending,8 it is also 
projected to cause up to thirteen million Americans 
to lose their health insurance before the end of 2010.9 
That also means that thousands of Americans will not 
be able to pay for prescription drugs that they once 
could afford under their health insurance plan.
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Payment for prescription drugs is one of the most 
controversial topics in the health care reform debate. 
In 2004, U.S. pharmacies filled “over 3.5 billion 
prescriptions.”10 In 2005, prescription drugs accounted 
for ten percent of health care dollars spent, double the 
5 percent of health care dollars spent in 1985, the 
largest increase by far among health care spending 
categories.11 Spending on prescription drugs in 
2005 grew by eleven billion dollars, or 5.8%.12 In 
total, in 2006, Americans spent over $216 billion on 
prescription drugs.13
1. Demographics
In the next several years, the aging American population 
and the rise in the proportion of seniors to working 
adults will force Americans to reform regulation of 
the prescription drug market to decrease the price 
of prescription drugs, thereby making the drugs 
affordable. The need for prescription drugs continues 
to rise among people of all ages and use increases 
with age.14 Between 2001 and 2004, over eighty-seven 
percent of persons sixty-five and older were taking at 
least one medication and almost sixty percent of the 
elderly were taking three or more.15 Between 2000 and 
2010, the population age sixty-five and over is expected 
to rise from 34,991,753 to 40,228,712, and between 
2010 and 2020, from 40,228,712 to 54,804,470.16 With 
this demographic shift, and the connection between 
age and use of prescription medications, the need for 
prescription drugs is likely to rise.
Among those with health insurance, however, even 
those age eighteen to sixty-four have had prescription 
drug care delayed or have forgone purchasing 
prescription drugs because of their high cost.17 Nine 
percent of eighteen to sixty-four year olds delayed 
or forewent prescription drug treatment due to cost 
while only 5.1% of those over age sixty-five delayed 
treatment and 3.6% did not get treatment.18 As the 
working population reaches age sixty-five and requires 
more prescription medication, those percentages will 
likely rise as well.
2. Methods of Payment
The way Americans pay for prescription drugs has 
also changed over the past thirty-five years. In 1970, 
seventy percent of payments for prescription drugs 
were private, out-of-pocket expenditures.19 By 2006, 
those payments fell to twenty-five percent, while 
private insurance payments for prescription drugs rose 
to forty-seven percent.20 This decrease resulted from 
expansion of benefits in both private health insurance 
plans and government programs, including the 
implementation of Medicare Part D in 2006.21 Despite 
the decrease in the share of health care expenditures 
paid out-of-pocket, continuing growth in health care 
costs means that consumers may continue to have 
significant out-of-pocket expenditures for prescription 
drugs.22
3. Price Increases
Statistics on prescription drug prices are relatively 
unreliable given the number of available drugs on the 
market. As of 2005, the FDA Orange Book23 contained 
11,706 approved prescription drugs.24 Two studies 
in particular on prescription drugs most commonly 
prescribed to Medicare patients, one conducted by the 
government and another by the American Association 
of Retired Persons (AARP) Public Policy Institute, 
show that real prices of prescription drugs subject to 
the study rose significantly and outpaced consumer 
prices.25
According to the study conducted in August 2005 
by the Government Accountability Office (GAO) 
examining trends for prescription drugs prices 
reported in New York and Pennsylvania, the retail cost 
to an uninsured purchaser of a thirty day supply of the 
ninety-six drugs most commonly prescribed under a 
large federal-worker insurance program increased by 
almost twenty-five percent between January 2000 and 
December 2004.26 The GAO updated the 2005 study 
in 2007 for a narrower group of prescription drugs 
to include data through January 2007, and found 
prices for brand-name drugs in that group “increased 
48.6 percent, [or] 5.8 percent average annual rate of 
increase,” outpacing the Consumer Price Index (CPI) 
which experienced a “9.9 percent, [or] 2.6 percent 
average annual rate of increase .”27 Tracking national 
drug price levels is difficult and unreliable, but the data 
show price increases in two of the largest prescription 
drug markets in the US over the last decade. Indeed, 
more comprehensive investigation of prescription 
drug prices is needed and has recently drawn support 
from Congress because of the effect on government 
programs.28
4. Pharmaceutical Industry Analysis
The pharmaceutical industry was the third most 
profitable private industry in the U.S. in 2008 and 
2009, with an almost twenty percent return of profit.29 
The ten most revenue producing prescription drugs in 
the U.S. in 2008 were all brand name drugs: Lipitor, 
Nexium, Plavix, Advair Diskus, Seroquel, Singulair, 
Enbrel, Actos, Prevacid, and Neulasta.30 About 
seventy-five percent of FDA-approved prescription 
drugs have generic counterparts.31 While cheaper 
generics are available for brand name drugs that have 
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lost exclusivity rights due to expiration of patents, generics are generally 
not available until patent rights expire.32
Lucrative profits, favorable tax credits and provisions, and the potential 
monopoly created by exclusivity in patent rights are characteristic of the 
pharmaceutical industry’s astronomical rise since the 1960s.33 While the U.S. 
government has a history of targeting direct and indirect subsidies towards 
particular industries, most notoriously agriculture,34 most economists agree 
that subsidies operate less in the interest of economic efficiency and more 
to protect domestic industries from foreign competition.35 Subsidies can 
help stabilize markets and raise return to investment, but such benefits 
have not been proven.36 Taxpayer and consumer dissatisfaction with the 
pharmaceutical industry can be traced to this mix of situational, private, 
and public factors that have contributed to the pharmaceutical industry’s 
prominence in the economy.37
a. A Public or Private Good?
The pharmaceutical industry is in a unique middle ground between public 
goods and private industry. Prescription drugs save and improve lives. 
Many Americans believe that health care is a public good. Millions of 
citizens in other countries already enjoy publicly provided health care, 
including publicly subsidized prescription drugs. A great number of 
Americans receive prescription drugs at a government-subsidized price 
through Medicare and Medicaid.
On the other hand, the prescription drug industry is, for the most part, 
a private industry funded by profits that are reinvested in research and 
development.38 Funds for research and development costs are the industry’s 
gift and curse. A lucrative new prescription drug can yield billions of dollars 
in revenue over the course of its lifetime as a brand name medication.39 Yet 
for every successfully developed drug, most will fail in either research or 
development, taking with them a large amount of fixed costs.40 According 
to the Pharmaceutical Research and Manufacturers of America (PhRMA), 
only one out of every 5000 drugs tested is eventually approved for use 
by the FDA, and it takes twelve to fifteen years to develop a new drug 
for market.41 The average cost of successful development of a new drug 
is $800 million.42 PhRMA further estimates that only thirty percent of 
drugs approved for use generate enough revenue to recoup the average 
development cost.43 These costs are a product of the complicated process 
of discovery or invention of new medicines, as well as FDA requirements 
for new drug approval, manufacture, and distribution.44 The incentive to 
research and develop with hopes of profitability is tempered by the assumed 
fixed cost risk of failed research and development.45
Conversely, pharmaceutical companies justify high prices, profits, and 
expenditures to the public by claiming that they develop a good that widely 
improves peoples’ health. In 2009, Pfizer, the world’s largest pharmaceutical 
manufacturer, stated its mission on the homepage of its company website:
At Pfizer, we’re inspired by a single goal: your health. That’s why 
we’re dedicated to developing new, safe medicines to prevent and 
treat the world’s most serious diseases. And why we are making them 
available to the people who need them most. We believe that from 
progress comes hope and the promise of a healthier world.46
It is one thing to argue that the high cost of research and development 
will be redistributed from producers to consumers through high prices. 
However, it is entirely different to create an environment, especially in a 
free-market economy, where producers generate limitless profits as a result 
of a government sanctioned system of approval, exclusivity, and subsidy, 
and consumers are given no alternative choices through restriction of 
competition and parallel trade.
Moreover, the Federal Trade Commission (FTC) has documented incidents 
of pharmaceutical companies attempting to distort further the market by 
compensating generic drug manufacturers for delaying the introduction 
of their lower cost products through patent infringement suit settlements, 
known as “reverse payment” agreements.47 This conflict is separate from 
the controversial FDA drug review process, in which pharmaceutical 
companies under review by the FDA fund their own approval programs 
through drug application user fees.48 In response to appellate court 
decisions upholding settlements between brand name and generic drug 
manufacturers, FTC investigators found that half of the settlements made 
in 2006 and 2007 included payments from the brand name company in 
exchange for a promise from the generic company to delay entry into the 
market.49 The same was true for over two-thirds of the settlements between 
brand name and generic companies with exclusivity rights blocking other 
generic drug applicants.50 The Preserve Access to Affordable Generics Act, 
introduced by Sen. Herb Kohl (D-WI) in February 2009, was proposed to 
prohibit such anti-competitive agreements.51 While the bill is one measure 
to protect the public from pharmaceutical companies’ underhanded 
behavior, a legal and regulatory balance must still be struck between the 
public good and the private market.
b. Breaking Down Expenditures
Research and development expenditures in the pharmaceutical industry are 
high, and companies recoup those costs by passing them on to consumers.52 
Evidence strongly suggests that, industry-wide, marketing expenditures for 
drugs equal or exceed research and development expenditures.53 According 
to a study by two researchers from York University, in 2004 pharmaceutical 
companies spent $57.5 billion on promotion and marketing.54 According 
to a National Science Foundation (NSF) report for the same year, 
pharmaceutical companies spent $31.5 billion (including public funds 
disbursed to the pharmaceutical industry) on domestic research and 
development.55 The York University study concluded that, as a percentage 
of the $235 billion in domestic prescription drug sales in 2004, promotion 
and marketing expenditures accounted for twenty-four percent of each 
sales dollar,56 while research and development spending accounted for 
thirteen percent.57
The NSF estimates may not take into account smaller firms that are not 
PhRMA members.58 These smaller firms are privately funded and driven 
by research and development.59 In the traditional model, biotechnology 
firms discover or develop a new drug then partner with a pharmaceutical 
manufacturer who markets and promotes the medication.60 In 2003, 
pharmaceutical and biotechnology firms listed on the Standard and Poor 
Compustat database spent roughly sixty billion dollars on research and 
development expenditures.61 Taking this estimate into account, even 
at the most conservative level, including firms with high research and 
development expenditures and little to no marketing expenditures in the 
pharmaceutical industry, marketing and promotion costs equal or exceed 
research and development.
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c. You Better Shop Around...But Can You?
The present regulatory environment surrounding U.S. pharmaceutical 
manufacturing allows American prescription drug prices to be the highest 
in the world. The U.S. “is the only major industrialized country in the world 
that does not currently regulate prescription drug prices.”62 In 2003, the 
Congressional Budget Office (CBO) estimated that, on average, foreign 
prices for prescription drugs were between forty-five percent and sixty-five 
percent lower than U.S. prices.63
Brand name drug costs are the primary driving factor behind the movement 
to legalize drug importation from foreign countries. One notorious example 
of an expensive brand name drug is Lipitor. A 20 mg tablet of Lipitor, the 
top revenue producing prescription medication in the U.S. in 2008,64 sold 
for four to five dollars in 2009 at CVS, the largest pharmacy chain in the 
U.S.65 In several other countries, including the United Kingdom, Israel, 
Canada, and New Zealand, the same prescription dosage of Lipitor sold for 
anywhere from $1.32 to $2.90.66 Even where U.S. consumers try to take 
advantage of lower prescription drug prices abroad, stringent regulation of 
prescription drug importation for personal use prevents them from doing 
so.
iii. drug importation and reimportation
Drug importation and reimportation policies have been proposed to 
address high drug prices in the U.S. Drug importation refers to the practice 
of importing prescription drugs manufactured outside of U.S. borders 
into the country.67 Drug reimportation refers to the practice of importing 
prescription drugs originally manufactured in the U.S. and then exported 
elsewhere back into the U.S.68 The terms are often used interchangeably, 
but under their precise legal definitions, mean different things.69
The Food, Drug, and Cosmetic Act70 of 1938 (FD&C Act) was passed to 
“prevent the adulteration, misbranding, and false advertising of food, drugs, 
devices, and cosmetics in interstate, foreign, and other commerce subject 
to the jurisdiction of the U.S., for the purposes of safeguarding public 
health and preventing deceit upon the purchasing public.”71 The FD&C Act 
is primarily concerned with ensuring that drugs in interstate commerce, 
including those that are imported or reimported, meet the FDA’s approval 
process.72 In 1984, to stimulate drug development and innovation, Congress 
passed the Drug Price Competition and Patent Term Restoration Act73 
(popularly known as the Hatch-Waxman Act).74 The Act provided up to five 
years of additional patent protection for prescription drug manufacturers to 
compensate for time spent in clinical trials and awaiting FDA approval.75 
The Act also allowed generic drug manufacturers to complete an abbreviated 
new drug application and forego testing requirements if the generic drug 
met certain equivalence standards.76
In 2000, Congress passed the Medicine Equity and Drug Safety Act77 
amending the FD&C Act, to allow drug importation in an effort to reduce 
medication prices.78 The statute contained an importation provision which 
then Secretary of the Department of Health and Human Services (HHS), 
Donna Shalala, had the authority to decertify if she determined that 
implementing the provision would “pose no additional risk to the public’s 
health and safety.”79 Secretary Shalala did in fact decertify the importation 
provision.80
The Pharmaceutical Market Access Act,81 first introduced in 2003 in the 
House by Rep. Gil Gutknecht, was designed to amend the FD&C Act and:
(1) Give all Americans immediate relief from the outrageously high 
cost of pharmaceuticals; (2) Reverse the perverse economics of the 
American pharmaceutical markets; (3) Allow the importation of 
drugs only if the drugs and the facilities where they are manufactured 
are approved by the Food and Drug Administration, and to 
exclude pharmaceutical narcotics; and (4) Require that imported 
prescription drugs be packaged and shipped using counterfeit-
resistant technologies approved by the Bureau of Engraving and 
Printing (technologies similar to those used to secure United States 
currency).82
The Act would authorize the Secretary of HHS to promulgate regulations 
for the importation of prescription drugs.83 Congressional findings in 
support of the Act stated that:
(1) Americans unjustly pay up to 1000 percent more to fill their 
prescriptions than consumers in other countries
(2) The United States is the world’s largest market for pharmaceuticals 
yet consumers still pay the world’s highest prices.
(3) An unaffordable drug is neither safe nor effective. Allowing and 
structuring the importation of prescription drugs ensures access 
to affordable drugs, thus providing a level of safety to American 
consumers they do not currently enjoy.
(4) According to the Congressional Budget Office, American seniors 
alone will spend $1.8 trillion dollars on pharmaceuticals over the next 
ten years.
(5) Allowing open pharmaceutical markets could save American 
consumers at least $635 billion of their own money each year.84
The Act passed in the House but failed in the Senate.85
Sen. Byron Dorgan (D-ND) introduced the latest bill in the string of 
congressional efforts to open U.S. borders to drug importation, the 
Pharmaceutical Market Access and Drug Safety Act of 2005.86 Amendments 
in the 2005 bill to Section 804 of the FD&C Act would require the Secretary 
of HHS to promulgate regulations allowing “qualifying individuals” to 
import prescription drug products covered under the legislation, but the bill 
was never passed.87
Conversely, also in 2005, Rep. Gregory Meeks (D-NY) independently 
introduced a concurrent resolution opposing legalizing personal drug 
importation. 88 While the resolution was never adopted, it reiterated many 
of the arguments against prescription drug importation and reimportation, 
including foreign price controls, the December 2004 HHS study on 
importation, the implications importation would have on the pharmacist/
patient relationship, and the lack of savings U.S. consumers would 
experience if importation were legal.89 However, the final finding stated that 
“[w]hereas despite significant efforts, including joint efforts with United 
States Customs and Border Protection and import alerts or bulletins, the 
Food and Drug Administration currently does not have sufficient resources 
to ensure adequate inspection of current levels and categories of personal 
shipments of prescription drugs entering the United States.”90
In an effort to include the legislation as an amendment to the current federal 
health care reform bill and capitalize on political momentum surrounding 
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the effort to increase access to health care and lower costs, Sen. Dorgan 
proposed his bill again in December 2009.91 According to Dorgan’s 
proposal, CBO estimated the bill would cut federal government costs by 
$19.4 billion by 2020, and save consumers one hundred billion dollars 
in the same span.92 Once again, the bill failed a floor vote,93 which was 
preceded by arguments from FDA Commissioner Margaret Hamburg to 
the Senate in opposition because, “as currently written,” the bill would be 
“logistically challenging to implement and resource intensive” and presents 
significant safety risks.94
Rep. Meeks’ resolution did not address current inadequacies in the regulatory 
system. Only two statements on the price issue related to large-scale 
changes. The first, placing the responsibility to lower prices on the industry, 
stated that “the pharmaceutical industry and the health care community 
should work to ensure that all citizens have access to prescription drugs with 
the same level of safety and efficacy guaranteed under the current system 
of regulation”95 (emphasis added). The second called for deregulation of 
foreign price controls to encourage the flow and sale of cheaper drugs into 
the U.S. for American consumers.96 Commissioner Hamburg’s two-page 
letter provided no solutions to the system’s inadequacies. Prescription drug 
importation and reimportation remain illegal in the U.S.97 A satisfactory 
version of the bill has yet to be enacted. More importantly for the purposes 
of this article, as displayed by its emphasis on the dangers of current and 
potential importation, the federal government has not taken sufficient 
action to address the difficulties in safely regulating illegal importation.
iV. fdA/PhArMA Arguments against importation/
reimportation
A. Pharmaceutical Companies: Decrease in Profits Leading to Loss of 
Incentive for Research and Development 
The general argument justifying why brand name prescription drug costs 
are highest in the U.S. is that there are extremely high fixed costs for 
research and development that must be recouped in revenue to provide an 
incentive for investment in future drugs.98 The fact that the industry spends 
an equal or greater amount on marketing and promotions than on research 
and development seriously undermines the argument that drug companies 
must protect their profits from being swallowed by the importation of drugs 
from countries with lower prices at the risk of losing the incentive to spend 
on the future development of new drugs.99 Pharmaceutical companies 
benefit from several important characteristics of the domestic market and 
domestic government regulation. As previously mentioned, unlike nearly 
every other industrialized nation with a pharmaceutical market, there are 
no price controls on prescription drugs in the U.S.100 Second, public funds 
are used for private pharmaceutical company research and development.101 
Third, the pharmaceutical industry lobby is one of the largest in the 
country. Finally, exclusivity through patent rights allows pharmaceutical 
manufacturers to sell their products without competition. 102 Given our 
country’s treatment of prescription medication as a mixed public/private 
good, these protections are unparalleled in any other industry.
B. Food and Drug Administration Safety Concerns: Counterfeit, Poor 
Quality, or Contaminated Drugs
The FDA and pharmaceutical companies also argue that legalized 
importation would threaten to circumvent FDA standards for drug safety.103 
The FDA’s statutory responsibility is to “assure the American public that 
the drug supply is safe, secure, and reliable.”104 Of primary concern to the 
FDA is that the “safety and effectiveness” of drugs from outside the closed 
legal and regulatory system in the U.S. cannot be ensured.105 Though there 
are no reliable data on the quantity or scale of counterfeit drug operations 
attempting to penetrate the U.S. border, the FDA claims that its number 
of counterfeit drug investigations have quadrupled since the late 1990s.106 
More recently, the rise in internet prescription drug sales and overseas 
counterfeiters with sophisticated technologies and criminal backed 
bankrolls have challenged the FDA to augment its efforts in securing the 
closed U.S. pharmaceutical distribution system.107
In 2006, the FDA published a consumer bulletin warning against purchasing 
prescription drugs from RxNorth, a company operating several websites 
based in Canada.108 The investigation is ongoing. Also in 2006, several 
defendants from Atlanta, Georgia, were indicted by a federal grand jury 
relating to a scheme to distribute unapproved versions of Ambien, Valium, 
Xanax, Cialis, Lipitor, Vioxx, and other drugs over the internet.109 The 
defendants opened a facility in Belize, manufactured over twenty-four 
different prescription drugs, and conspired to market the drugs through 
e-mail advertisements claiming the drugs were Canadian generics.110 
In 2005, a group of businesses and individuals were indicted in the 
Western District of Missouri for involvement in a forty-two million dollar 
conspiracy to distribute counterfeit Lipitor manufactured at a facility in 
Central America and genuine Lipitor purchased in Central America.111 The 
increase of large scale sophisticated counterfeiting operations, smuggling, 
and internet sales reveal the greater issue — that more resources must be 
expended in the regulation of prescription drugs across U.S. borders.
Information on the safety of illegally imported prescription drugs is “very 
limited” — no agency of the federal government systematically collects 
data on the volume of prescription drug imports.112 According to an HHS 
report in December 2004, approximately ten million packages containing 
prescription drugs enter the U.S. annually from all over the world.113 
However, the GAO has condemned the findings as based on extrapolation 
of limited data, and thus unreliable.114
The FDA is extremely under-funded, but is “doing its best to use its limited 
international authorities to stop the increasing flow of violative drugs into 
this country” because “the sheer volume [of illegally imported prescription 
drugs] has grown to exceed the capability of FDA field personnel to 
properly process.”115 To address this growing health risk, the FDA has 
responded to the threats imposed by importation by “employing a risk-
based enforcement strategy to target [their] existing enforcement resources 
effectively in the face of multiple priorities, including homeland security, 
food safety, and counterfeit drugs.”116 The current system “is already 
overwhelmed by the number of incoming packages, and this presents a 
significant ongoing challenge for the Agency.”117 The volume of imported 
prescription drugs expected to rise suggests that the current strategy must 
be significantly revamped or abandoned.
V. U.s. regulation of importation/reimportation
The most influential actor in the prescription drug industry is the federal 
government. Legal and regulatory protections allowing the prescription drug 
market to continue operating in a closed system and generating increased 
profits must be re-examined. This section will delve into the responsibilities 
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and resources of federal agencies that regulate the importation of goods 
into U.S. borders and compare their magnitude and effectiveness.
The FDA “coordinates with other governmental bodies and meets regularly 
with other federal agencies and state officials to share information 
and identify opportunities for partnering in enforcement actions.”118 
U.S. Customs and Border Protection (CBP), U.S. Drug Enforcement 
Administration (DEA), U.S. Immigration and Customs Enforcement (ICE) 
are among the FDA’s federal agency partners.119 The FDA maintains these 
relationships, among other reasons, to “leverage resources and best protect 
American consumers.”120 These federal agencies all share a congressionally 
delegated duty to protect our borders from harmful threats.
A. FDA Regulation of Importation
The FD&C Act authorizes the FDA to oversee the production of drugs that 
meet approved standards, whether manufactured in the U.S. or abroad.121 
Legally imported drugs are introduced to the U.S. market only through 
FDA-approved manufacturing facilities and methods.122 The FD&C Act 
outlines a list of prohibited acts that include introducing any adulterated 
or misbranded food or drug into interstate commerce and causing a drug to 
be a counterfeit drug, selling, dispensing, or holding for sale or dispensing 
a counterfeit drug.123 Violation can result in a court ordered injunction, 
or civil or criminal liability for all those who caused, aided or abetted, or 
conspired in one of the prohibited acts.124 According to the FDA, by failing 
to legalize prescription drug importation, Congress has concluded “that 
the safety and effectiveness of imported drugs is best assured by carefully 
limiting how prescription drugs can be imported in the U.S. as part of a 
closed drug distribution system.”125
1. Personal Importation at Points of Entry
Under limited circumstances, an individual entering or returning to the 
U.S. may personally import new prescription drugs, even those that 
are unapproved, if their situation meets certain exigency standards and 
documentation required by the FDA.126 According to a statement on its 
website in 1998, the FDA, on its own initiative, developed guidance on 
personal importation in its Regulation Procedures Manual (RPM) entitled 
“Coverage of Personal Importations”.127 The purpose of the guidelines 
is to provide guidance on allowing personal-use quantities of FDA-
approved imported products in baggage and mail and “to gain the greatest 
degree of public protection with allocated resources.”128 The importation 
policy states that “because the amount of merchandise imported into the 
[U.S.] in personal shipments is normally small, both in size and value, 
comprehensive coverage of these imports is normally not justified.”129 
The FDA has focused its enforcement priorities on commercially shipped 
products, including small mail-order solicitations, which are not subject to 
these RPM guidelines. They have focused “less on those products that are 
personally carried, shipped by a personal non-commercial representative of 
a consignee, or shipped from foreign medical facility where a person has 
undergone treatment.”130
The guidelines themselves allow for significant discretion in accepting a 
personal importation of an unapproved drug into the U.S. “when the quantity 
and purpose are clearly for personal use, and the product does not present 
an unreasonable risk to the user.”131 Stressing that RPM guidelines “are 
intended only to provide operating guidance for FDA personnel and are not 
intended to create or confer any rights, privileges, or benefits on or for any 
private person,” the statement goes on to describe situations where personal 
importation may be allowed at FDA agents’ discretion.132 Examples 
given in the guidelines include a person who has started treatment with 
an unapproved drug in a foreign country, has an “ethnic background” and 
prefers products from his or her homeland or labels in their native language, 
or suffers from a condition for which there is no FDA-approved drug.133
In two cases, FDA personnel may act permissively in deciding whether to 
allow the personal importation. In the first case, when an agent identifies 
the drug’s intended use as appropriate, for example for treatment of a non-
serious condition, and “the product is not known to represent a significant 
health risk,” the agent may exercise wide discretion.134 In the second case, 
wide discretion may be exercised where:
a) the intended use is unapproved and for a serious condition for 
which effective treatment may not be available domestically either 
through commercial or clinical means; b) there is no known 
commercialization or promotion to persons residing in the U.S. 
by those involved in the distribution of the product at issue; c) the 
product is considered not to represent an unreasonable risk; and d) 
the individual seeking to import the product affirms in writing that it 
is for the patient’s own use (generally not more than 3 month supply) 
and provides the name and address of the doctor licensed in the U.S. 
responsible for his or her treatment with the product, or provides 
evidence that the product is for the continuation of a treatment begun 
in a foreign country.135
Should the agent have questions about any situation, the guidelines advise 
him or her to hold the drug and “consult with the appropriate headquarters 
office.”136
FDA personnel are instructed “not to examine personal baggage.”137 CBP 
officers are responsible for examining baggage and will notify their local 
FDA office when they have identified an FDA-regulated drug intended for 
commercial distribution or an FDA-regulated drug that may represent a 
risk to public health.138 FDA agents are responsible for regulating mail 
importations, but only after CBP sets them aside following an initial 
determination that they may be in violation of the FD&C Act.139
2. Importation at Mail Facilities
According to the 2004 HHS report, CBP and FDA officials at certain 
mail facilities used different practices and procedures to inspect packages 
containing prescription drugs.140 The basis upon which packages were 
targeted varied based on several subjective and objective factors, such as the 
inspector’s intuition and experience, whether packages came from suspect 
countries or companies, and whether shipments were to individuals.141 
While some illicit packages were inspected and seized, many others either 
were not inspected and released immediately or were released after being 
held for inspection.142 Because they were unable to process the volume of 
packages, FDA officials released tens of thousands of packages containing 
prescription drug products that could have posed a health risk to American 
consumers.143
In response to the observational study on mail facilities, the FDA issued new 
nationwide procedures outlining how FDA agents are to prioritize packages 
for inspection, inspect the packages, and determine whether FDA-regulated 
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pharmaceuticals should be allowed into the U.S. by mail.144 CBP personnel 
are required to forward any mail from FDA’s national list of targeted 
countries that appear to contain prescription drugs to FDA agents.145 CBP 
inspectors must request and have FDA management approve a deviation 
from this requirement.146 Still, related testimony before Congress revealed 
that “[w]hile the new procedures should encourage processing uniformity 
across facilities, many packages that contain prescription drugs are still 
released,” because all packages CBP forwards to the FDA that FDA 
inspectors do not process at the end of each day are returned to the U.S. 
Postal Service (USPS) for delivery.147
Perhaps the most important fact in the HHS report was the finding that 
there was only the equivalent of seventeen full time FDA employees whose 
responsibility it was to inspect all of the international mail facilities in the 
U.S. for counterfeit drugs.148 When twenty to thirty million packages enter 
our borders through USPS each year, 149 this level of taxpayer resources 
devoted to drug regulation in the interest of public health and safety is 
completely unacceptable. Shockingly, these measures are being practiced 
with the importation ban still in effect. It is estimated that more than 
3.5 to 350 million U.S. prescriptions could be affected by counterfeit or 
substandard drugs each year.150 As the number of prescriptions filled in 
the U.S. continues to climb, a significant increase in resources allocated 
to regulating importation is even more justified today than when the FDA 
developed its RPM guidelines. While it may be true that implementing an 
anti-counterfeit system as outlined in the Pharmaceutical Market Access 
Act would not be justified in terms of a decrease in prices for American 
consumers, available resources should be put towards strengthening our 
nation’s current regulation of drug importation.
3. Budget Allocations
Dollar amounts and manpower allocated to the regulation of drug 
importation are also telling. In the 2009 fiscal year, the FDA requested 
from Congress a total budget of $2.4 billion, which includes $1.77 billion 
in budget authority and $628 million in industry user fees.151 This amount 
is $129.7 million more than in fiscal year 2008 budget, a 5.7% increase.152 
The proposal included “strategic increases to strengthen food protection, 
modernize drug safety, speed approval of generic drugs, and improve 
the safety and review of medical devices.”153 Between October 2008 and 
September 2009, the FDA was projected to experience a full-time equivalent 
staff increase of 526 employees.154 The FY 2010 budget includes a request 
for the largest increase in FDA funding history, calling for a total budget 
of $3.2 billion.155 This represents a nineteen percent increase from 2009,156 
and for comparison, almost four times the percentage increase from 2008 
to 2009.
The FDA Human Drugs Program (HDP) is authorized to ensure that 
prescription, generic, and over-the-counter (OTC) drug products are 
adequately available to the public and are safe and effective.157 The HDP is 
responsible for monitoring drug products for unexpected health risks and for 
enforcing the quality of drug products.158 The HDP received roughly $777 
million for its total budget in 2009 and requested $908 million in 2010.159 
The HDP operates with assistance from the FDA Office of Regulatory 
Affairs (ORA), which provides leadership on import and inspection 
policies.160 In 2009, the ORA received $725 million for its total budget, 
a roughly twelve percent increase over 2008.161 Through its field offices, 
ORA supports the HDP by conducting domestic and foreign inspections 
of drug manufacturers to assess their compliance with manufacturing 
standards and investigating incidents of product tampering that may affect 
FDA-regulated goods.162
Where criminal activity is involved, ORA’s Office of Criminal Investigations 
(OCI) complements the ORA Field Drug Program (FDP).163 Both 
appropriations and user fees fund the FDP.164 The amount allocated to the 
FDP in the 2010 budget request is just under $145 million and supports 763 
full time employees, an increase of roughly twenty-seven million dollars 
and sixty-four employees over 2009.165
The 2009 allocation to the FDP included funding for an initiative targeting 
post-manufacture prescription drug safety by monitoring imported 
prescription drugs.166 Designed to combat an FDA estimated twelve 
percent increase in the volume of imported pharmaceutical drugs in 2009, 
the funding increase was designed to allow the FDP to “support three 
new agents to investigate criminal drug import violations.”167 Thus, of the 
expected increase of 526 new full time FDA staff, only three will have the 
responsibility of investigating criminal importation.
Fortunately, in both criminal and civilian drug importation cases, ORA 
coordinates import activities with CBP. However, the FDA explicitly 
acknowledges in its budget documents that security concerns and the 
increase in the number of imports make the task of regulation difficult with 
the current amount of resources the FDA receives.168 In fiscal year 2010, the 
FDA projects a total of 20.5 million import lines, two percent (or 410,000) 
of which will be human drugs and biologic products.169 That is hardly 
an acceptable workload for so few personnel. Such a meager increase, 
combined with the assignment of three new field agents, is an unreasonable 
response to a problem the FDA acknowledges is growing exponentially. 
Notably, the budget includes five million dollars for “the FDA to develop 
policies to allow Americans to buy drugs approved in other countries.”170 
While this is a step in the direction of acknowledging importation as a 
possible solution, the budget makes no explicit mention of a related full 
time employee increase, and within the budget justification there is only 
one explanation of what development will take place. 171 In 2010, of the 
five million dollars dedicated to developing import policies generally, 
only one million dollars is allocated to the FDP,172 a disappointing number 
considering the historic increase and the need to improve effectiveness of 
any effort to strengthen current importation enforcement policy.173
B. U.S. Customs and Border Protection Regulation
The FDA and the CBP work together on several fronts to examine products 
entering U.S. borders, protect the American public from foreign health risks, 
and enforce the laws of the U.S. against illegal activity and international 
threats.174 On March 1, 2003, all immigration inspectors, agricultural 
border inspectors, and the border patrol merged with U.S. Customs to form 
the U.S. Customs and Border Protection agency within DHS.175 There are 
now four agencies within DHS charged with securing U.S. borders: CBP, 
the Bureau of Immigration and Customs Enforcement (ICE), the U.S. 
Coast Guard, and the Transportation Security Administration (TSA).176 
The merger was part of both Title VI of the Customs Modernization Act 
(also known as the Mod Act), 177 enacted as part of NAFTA implementing 
legislation in 1993, and the Homeland Security Act of 2002.178 With the 
creation of CBP, all arms of the federal government with significant border 
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enforcement responsibilities were unified into one agency for the first time 
in U.S. history.179
1. CBP by the Numbers
In 2008, there were over 19,726 U.S. Customs inspectors and canine 
enforcement officers.180 In fiscal year 2008, CBP inspectors logged more 
than thirty million entries of commercial imports.181 To fund its growing 
operations, CBP’s budget request for fiscal year 2009 represented an 
increase of $1.66 billion, or 17.9% over 2008, and totals $10.94 billion — 
$1.45 billion of which was to be collected through user fees.182 In contrast, 
the 2008 budget request represented a nine percent increase over fiscal 
year 2007.183 The only highlight in the CBP 2008 fiscal year in review 
statement relating to consumer import safety states that CBP “established 
a dedicated import safety branch and worked closely with other federal 
agencies to protect the American public from unsafe . . . imported products. 
CBP collocated [sic] Consumer Product Safety Commission personnel at 
several of our ports of entry to improve targeting and information sharing 
between the agencies.”184
2. Proposed CBP Policies
In a 2005 report to Congress, the GAO made several recommendations to 
the various agencies responsible for regulating prescription drug imports.185 
The overarching idea was to require a CBP task force involving ICE, FDA, 
USPS, DEA, and the Office of National Drug Control Policy to develop a 
strategic framework to help formulate policy reforms.186 First, the GAO 
recommended that the task force establish an approach for estimating 
the scope of the prescription drug problem, particularly the volume of 
drugs entering the country through mail and carrier facilities.187 Second, 
to estimate the scope of the problem, the task force would gauge results 
by establishing objectives, milestones, and performance measures and a 
methodology to gauge results.188 Third, the task force would determine 
the resources needed to address the flow of illegally imported prescription 
drugs and where those resources should be targeted.189 Fourth, the task 
force would evaluate progress, identify barriers to achieving goals, and 
suggest modifications to the current regulatory system.190 As a final and 
unrelated suggestion, the GAO recommended that the Secretary of HHS 
re-examine and provide a report on removing or modifying the requirement 
that the FDA must allow personal importers the opportunity to provide 
documentation that their prescription drugs are legitimate.191
 Implementation of these recommendations is ongoing, but has yet to be 
fully achieved. For example, in response to the second recommendation, 
CBP claimed it had developed a document that contains a mission statement, 
outlines the responsibilities of the various agencies, and presents objectives, 
milestones, and performance measures.192 According to the GAO, however, 
the CBP document does not: establish concrete milestones including target 
dates by which tasks should be completed, outline performance measures 
that CBP and other agencies can use to gauge performance and results, 
or show what resources are needed to address the problem and where 
resources should be targeted.193 While the recommendations did not give 
detailed instructions, four years is not an unreasonable time to allow a 
federal agency to work in conjunction with other agencies and develop 
documents to address an increasing problem. Because the FDA claims it 
faces a higher incidence of unapproved drugs entering U.S. borders with 
no additional funding, there must be both a greater sense of urgency 
and a policy response not only from government agencies but also from 
legislators and the President to reform drug regulation.
One positive example of CBP and FDA joint operations shows that 
increased coordination between the agencies in terms of both manpower 
and technology can be fruitful. Pursuant to an agreement between CBP 
and the FDA, the FDA is allowed to commission CBP officers to assist the 
FDA with examination and investigation of food imports when importers 
provide prior notice of importation as part of the Bioterrorism Act.194 
The agreement also requires that the FDA provide appropriate training to 
commissioned CBP inspectors, provide twenty-four hour assistance to CBP, 
reimburse CBP for costs associated with examination and investigation, 
share information, and jointly develop additional agreements to implement 
the agreement’s purpose.195 In addition to providing FDA with manpower, 
CBP is required to collect samples for analysis, or analyze samples 
themselves, to detect illegitimate food imports.196
Again, data are difficult to collect on the effectiveness of measures involving 
import interdiction. Training border personnel in multiple areas of regulation 
is one cost-effective method of increasing the federal government’s ability 
to regulate imports. By having agents who are independently capable of 
examining, investigating, and detaining goods that they determine may be 
illicit, counterfeit, or a health risk, the FDA will better be able to make use 
of limited resources. Placing more efficient FDA or CBP personnel on the 
frontlines could lower costs in the long run and create high-skilled jobs.
C. TSA Regulation of Commercial Air Travel
Congress created the TSA in response to the September 11, 2001 terrorist 
attacks and charged the DHS agency with protecting U.S. air and ground 
transportation to ensure freedom of movement for people and goods.197 
Under authority of the Aviation and Transportation Security Act, the TSA 
established a baggage screener workforce and took over the responsibility of 
screening domestic commercial air passengers and bags from commercial 
air carriers. 198 CBP remains responsible for screening international 
commercial air travelers.
The TSA’s budget request for fiscal year 2009 was $7.1 billion, a total 
increase of $286 million over the fiscal year 2008.199 Of the total amount 
requested, $5.3 billion went toward aviation security.200 Beginning as a 
relatively small agency, the TSA now employs over 50,000 people.201 The 
TSA provides a valuable example of effective hiring and training measures 
for inspections agents to increase manpower. In building its workforce 
essentially from the bottom up, TSA began by hiring and training the first 
federal screeners, known as Transportation Security Officers (TSOs) in 
airports and charged them with stopping simple prohibited items including 
razors and firearms.202 TSOs are now “highly-trained, multi-skilled” 
agents that perform physical and behavioral screening using sophisticated 
screening equipment throughout airports nationwide.203
In 2006, TSA screened 708,400,522 people through airport security, 
535,020,271 individual pieces of checked luggage, and opened and 
examined 85,571,710 bags for prohibited items.204 The TSA attributes 
its effectiveness in training and retaining TSOs to a number of initiatives, 
including: career development, attrition reduction, and workplace safety 
measures.205 In particular, to address inadequacies in field offices, TSA 
requires field offices to maintain a Model Workplace Program to improve 
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their employees’ work environment. This has reduced full-time attrition 
from 13.6% in 2004 to 11.6% in 2007 and part-time attrition from 57.8% 
in 2004 to 37.2% in 2007.206 The TSA also changed its centralized hiring 
process to the local airport level, reducing hiring cost per TSO by over 
thirty-six percent from 2004 to 2007.207
Vi. reforms
Drug importation and reimportation may be an adequate solution to 
the problem of escalating and unaffordable prescription drug prices. 
Regardless of whether importation is the answer, there are existing issues 
within the FDA that must be addressed to solve current inadequacies in 
drug regulation.
In theory, government funding is a finite resource which must be 
appropriated to agencies and programs in a manner commensurate with 
their importance to and effectiveness at addressing problems. Looking at 
the resources the government applies to certain government measures in 
relation to others should provide the American people, both with an idea 
of what problems the government currently finds most pressing and how 
pressing those problems are as determined by the amount of funding they 
receive. Furthermore, with the current rate at which the government is 
spending on economic stimulus,208 there are plenty of funds available if 
the government deems a problem to be urgent enough for the well-being 
of the nation.
A safe supply of prescription drugs is a legitimate government interest, as 
are safe commercial air travel and the safety of all imported products. In the 
absence of accurate data on the incidence of unsafe or counterfeit goods, 209 
determining how many resources should be funneled is largely a subjective 
exercise. To the American people, prescription drugs, which accounted 
for over $216 billion in sales in 2008,210 are an incredibly important and 
growing expense as the population continues to age.211
Breaches in border safety are incredibly difficult to measure because there 
are no methods to gauge how many illicit goods go undetected.212 Gauging 
the magnitude of the prescription drug problem is difficult because drugs 
can be imported through the mail or carried across the border.213 As the 
GAO recommended to the CBP, creating a network or database to accurately 
determine how many illicit prescription drugs enter U.S. borders should be 
the first step.214
The FDA is inhibited by three factors in the battle against unapproved, 
unsafe, or counterfeit prescription drugs: lack of adequate funding, lack of 
adequate manpower, and inefficient processes.215 There are several lessons 
the government can take from other measures used in regulation of people 
and products at our borders. While DHS, CBP, and TSA are not perfect, 
each presents a valuable method the FDA could adopt in increasing its 
abilities to combat safety issues in prescription drug importation.
1. Funding
Lack of funding is at the top of the list of FDA deficiencies. The FY 2009 
FDA budget request was a 5.7% increase over fiscal year 2008 budget,216 
a relatively small increase in comparison to the 2009 CBP request, which 
jumped 17.9% over 2008.217 The TSA’s budget request for fiscal year 2009 
was $7.1 billion, a total increase of $286 million over fiscal year 2008 that 
more closely resembles the FDA’s relative increase from 2008.218 Of the 
total amount requested, seventy-five percent went toward Aviation Security, 
one program within the TSA.219
Although it is difficult to compare funding measures of these three agencies 
because of differences in the number of incidences of total examinations 
and inspections — up to fifty million for the FDA, eighty-five million for 
the TSA, and thirty million for CBP220 — there have almost certainly been 
more incidences of illegal importation of goods, including prescription 
drugs, than there have been terrorist threats on aircrafts in the U.S. since 
2008.221 This is not an argument that the TSA should receive less funding, 
but there must be a more proportionate amount of funding to the level and 
magnitude of the risk at issue. The one million dollar budget allocation 
to the FDP for development of a drug importation user fee is especially 
disappointing.222 If FDA concerns for drug safety are so pressing, more 
funding must be allocated. While the 2010 funding increase is a landmark 
step,223 it remains to be seen how far that step will go toward actually 
increasing enforcement of drug safety.
2. Manpower
FDA manpower and efficient use of that manpower must also be increased. 
While the FDA has greatly expanded its hiring of scientists, doctors and 
statisticians since 2007,224 field agents must become a priority. Physical 
examination is the only current method available to seize unsafe prescription 
drugs at import points of entry.225 Between October 2008 and September 
2009, the FDA was to experience a full-time equivalent staff increase of 
526 and of those, only three new agents were to be hired to investigate 
criminal drug import violations as part of the FDA’s FDP (there was no 
mention of an increase in the number of agents responsible for investigating 
personal importation).226
This issue provides a chance for the government to create highly skilled 
jobs in a time when many government agencies, especially those dedicated 
to security, are understaffed. Agreements like the one between CBP and 
the FDA on commissioning and training agents in multiple disciplines 
are a good starting point in addressing the lack of personnel available to 
process the massive amount of imports.227 The problem must be addressed 
at different levels. Implementing new hiring practices at the local level 
in individual mail facilities and improving retention to eliminate hiring 
costs, as the TSA has done,228 would be an excellent starting point to cut 
administrative costs while creating jobs.
Job creation must be part of the equation to solve the problem of inadequate 
manpower. For example, the number of full time FDA personnel examining 
all drug imports at international mail facilities around the country must be 
increased from seventeen.229 Such a number is completely unacceptable. 
The result, that at one facility roughly 10,000 packages a week are returned 
to USPS for delivery, is equally unacceptable.230 At least some FDA 
personnel should be positioned onsite, rather than stationed in the field 
office and called to the mail facility when a USPS or CBP agent determines 
a package should be held.231
3. Processes
To ensure that adequate funding and sufficient manpower are put to 
productive use, the FDA and other agencies involved must formulate a plan 
to address the importation dilemma that includes more efficient processes. 
First, the GAO recommendations to CBP must be completed.232 Since 2005, 
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none of the four recommendations the GAO proposed have been adequately 
met.233 Five years is far too long to fail to achieve a basic framework for 
developing new policies. Congress, especially those proponents of personal 
prescription drug importation, must push these agencies to complete the 
task.
On the enforcement level, the FDA and CBP must put in place more 
effective procedures for inspection of personal drug importation. The FDA 
has focused its enforcement efforts on commercial rather than personal 
shipments because the value and size of those imports do not justify a 
more complete inspection process.234 This argument is entirely resource-
based and shifts the focus away from the FDA’s concern about consumer 
product safety. As mentioned above, the system is in need of restructuring 
or abandonment235 combined with an increase in available agents to 
inspect both commercial and personal shipments at adequate levels. When 
this article was submitted for publication, FDA Commissioner Hamburg 
announced that in 2010, the FDA would begin using an improved risk-
based database, the PREDICT system, to replace its current import 
documentation database.236 Implementation of the PREDICT system 
shows that the FDA has sought methods to improve the inspection process. 
It will be interesting to see how PREDICT improves FDA’s ability to detect 
illicit imported prescription drugs.237
In practice, a determination for importation is a judgment that must be 
made quickly. Risk-based database tracking, due to the varying nature of 
regulation of international mail,238 cannot target the continuing problem 
of lack of resources allocated to international mail facilities. The FDA has 
yet to propose a solution to this problem (perhaps there is no systematic 
solution), but the lack of sufficient manpower is evident.239 As for personal 
importation policy, in the interest of pragmatism, allowing agents a 
significant amount of discretion in the RPM guidelines is good policy 
because of the subjective nature of the inquiry.240 Though “we cannot 
inspect our way to safety,”241 agencies can improve methods and augment 
the ability to meet the increasing numbers of illicit imported prescription 
drugs.
Vii. Conclusion
Why are we as a society so unwilling to devote the necessary resources to 
devise and implement quality control measures in an industry like health 
care, where quality services and pharmaceuticals are the only means of 
survival for millions of Americans? We as a nation are at a crossroads. The 
depth of the current economic recession increases the likelihood that the 
American people will demand health care reform at a greater pace than 
governments are currently undertaking. Though the FDA claims safety 
cannot be assured if personal importation is legal, it cannot effectively 
regulate the current in flow of prescription drugs through international mail, 
commercial shipment, or consumer importation at border points of entry. 
The FDA and CBP must establish a method to gauge the magnitude of the 
problem. They have failed in this regard. No measures for improvement will 
be possible or effective until the degree of the problem can be understood. 
Funding, manpower, and processes must be reformed to address the 
current inadequacies in prescription drug regulation. Increased funding, 
job creation, multi-disciplinary training, and on-site personnel are possible 
answers to the problems.
The amount of prescription drugs entering the U.S has increased 
substantially in the past twenty years and will undoubtedly continue to 
increase in the foreseeable future.242 Market forces will force America 
to fundamentally change how we regulate the pharmaceutical industry, 
prescription drug prices, and the safety of imported drugs. Drug importation 
and reimportation may very well be an adequate solution to the problem of 
escalating and unaffordable prescription drug prices. Regardless of whether 
importation is the answer, we must put our money where our mouth is and 
address existing issues to solve current inadequacies in imported drug 
regulation.
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